Elias K Mai

Optimizing oncology drug development: systematic review of 22 years of myeloma gerandomiseerde controlled trials.

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple ...

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Mul...

Elotuzumab plus VRd plus ASCT bij myeloom: GMMG-HD6 fase III

Isatuximab plus VRd als inductie bij transplanteerbaar myeloom: GMMG-HD7 fase III